Cargando…

Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential

INTRODUCTION: Triple-negative breast cancer (TNBC) is a subtype of highly malignant breast cancer with poor prognosis. TNBC is not amenable to endocrine therapy and often exhibit resistance to current chemotherapeutic agents, therefore, further understanding of the biological properties of these can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelicano, Hélène, Zhang, Wan, Liu, Jinyun, Hammoudi, Naima, Dai, Jiale, Xu, Rui-Hua, Pusztai, Lajos, Huang, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303115/ https://www.ncbi.nlm.nih.gov/pubmed/25209360 http://dx.doi.org/10.1186/s13058-014-0434-6

Ejemplares similares

Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins
por: Ma, Jing, et al.
Publicado: (2023)

Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas
por: Maniscalco, Lorella, et al.
Publicado: (2013)

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
por: Prvanović, Mirjana, et al.
Publicado: (2021)

New Insights into the Role of Exercise in Inhibiting mTOR Signaling in Triple-Negative Breast Cancer
por: Agostini, Deborah, et al.
Publicado: (2018)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

Pseudolaric acid B induces apoptosis associated with the mitochondrial and PI3K/AKT/mTOR pathways in triple‑negative breast cancer
por: Yang, Ke, et al.
Publicado: (2023)

Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38
por: Gohr, Katharina, et al.
Publicado: (2017)

Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer
por: Karn, Thomas, et al.
Publicado: (2014)

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
por: He, Jichao, et al.
Publicado: (2019)

Promotion of colorectal cancer cell death by ezetimibe via mTOR signaling-dependent mitochondrial dysfunction
por: Zheng, Yuanyuan, et al.
Publicado: (2023)

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers
por: Hatem, Rana, et al.
Publicado: (2016)

Rosemary Extract Inhibits Proliferation, Survival, Akt, and mTOR Signaling in Triple-Negative Breast Cancer Cells
por: Jaglanian, Alina, et al.
Publicado: (2020)

Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
por: Anand, Kartik, et al.
Publicado: (2021)

TMEM176B Regulates AKT/mTOR Signaling and Tumor Growth in Triple-Negative Breast Cancer
por: Kang, Chifei, et al.
Publicado: (2021)

mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders
por: Ryskalin, Larisa, et al.
Publicado: (2018)

Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality
por: Zhang, Wenfeng, et al.
Publicado: (2019)

Exploring mTOR inhibition as treatment for mitochondrial disease
por: Sage‐Schwaede, Abigail, et al.
Publicado: (2019)

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
por: Wali, Vikram B., et al.
Publicado: (2019)

mTOR Signaling Pathway in Bone Diseases Associated with Hyperglycemia
por: Wang, Shuangcheng, et al.
Publicado: (2023)

Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition
por: Zhang, Haiyu, et al.
Publicado: (2014)

mTOR coordinates protein synthesis, mitochondrial activity and proliferation
por: Morita, Masahiro, et al.
Publicado: (2015)

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
por: Jiang, Tingting, et al.
Publicado: (2016)

Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma
por: Merimsky, Ofer, et al.
Publicado: (2008)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

DEK promoted EMT and angiogenesis through regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Yang, Yang, et al.
Publicado: (2017)

Arnicolide D Inhibits Triple Negative Breast Cancer Cell Proliferation by Suppression of Akt/mTOR and STAT3 Signaling Pathways
por: Qu, Zhao, et al.
Publicado: (2020)

Dysfunction of the mTOR pathway is a risk factor for Alzheimer’s disease
por: Yates, Sharon C, et al.
Publicado: (2013)

mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging
por: Van Skike, Candice E., et al.
Publicado: (2019)

Aliskiren attenuates cardiac dysfunction by modulation of the mTOR and apoptosis pathways
por: Zhao, Zhengbo, et al.
Publicado: (2020)

Inhibition of mTOR improves malnutrition induced hepatic metabolic dysfunction
por: Arvidsson Kvissberg, Matilda E., et al.
Publicado: (2022)

Vaginal epithelial dysfunction is mediated by the microbiome, metabolome, and mTOR signaling
por: Berard, Alicia R., et al.
Publicado: (2023)

mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions
por: Cosialls, Emma, et al.
Publicado: (2023)

Mitochondrial AKAP1 supports mTOR pathway and tumor growth
por: Rinaldi, Laura, et al.
Publicado: (2017)

The Mitochondrial Deubiquitinase USP30 Regulates AKT/mTOR Signaling
por: Zhang, Ruohan, et al.
Publicado: (2022)

mTOR-regulated mitochondrial metabolism limits mycobacterium-induced cytotoxicity
por: Pagán, Antonio J., et al.
Publicado: (2022)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer
por: Mazumdar, Abhijit, et al.
Publicado: (2022)

Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers
por: O’Meara, Tess, et al.
Publicado: (2020)

Estrogen Regulation of mTOR Signaling and Mitochondrial Function in Invasive Lobular Carcinoma Cell Lines Requires WNT4
por: Shackleford, Madeleine T., et al.
Publicado: (2020)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1fipm0qpts0vcuqsr3m0bfvl44